A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy

Castration Resistant ◽

Transdermal Estradiol ◽

Faculty Opinions recommendation of A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3350956.3039058 ◽

2010 ◽

Author(s):

Yoshihiko Hirao ◽

Kiyohide Fujimoto

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Transdermal Estradiol ◽

Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.5017 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5017-5017 ◽

Cited By ~ 8

Author(s):

Johann S. De Bono ◽

Ugo De Giorgi ◽

Christophe Massard ◽

Sergio Bracarda ◽

Ivo Kocak ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Randomized Phase Ii ◽

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdx487 ◽

2017 ◽

Vol 28 (11) ◽

pp. 2741-2746 ◽

Cited By ~ 7

Author(s):

K. Fizazi ◽

A. Ulys ◽

L. Sengeløv ◽

M. Moe ◽

S. Ladoire ◽

...

Keyword(s):

Prostate Cancer ◽

Maintenance Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-12-2605 ◽

2012 ◽

Vol 19 (1) ◽

pp. 215-224 ◽

Cited By ~ 58

Author(s):

Charles J. Ryan ◽

Mark Rosenthal ◽

Siobhan Ng ◽

Joshi Alumkal ◽

Joel Picus ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Biomarker Analysis

MP87-11 INTERIM ANALYSIS OF AN OPEN LABEL PHASE II STUDY OF ENZALUTAMIDE AND RADIUM RA 233 DICHLORIDE IN SYMPTOMATIC, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS.

The Journal of Urology ◽

10.1016/j.juro.2018.02.2911 ◽

2018 ◽

Vol 199 (4S) ◽

Author(s):

Neal Shore ◽

Paul Schellhammer ◽

Ronald Tutrone ◽

Neil Mariados ◽

Stacey Harrelson

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Study ◽

Open Label ◽

Castration Resistant ◽

Open Label Phase

TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT)

Annals of Oncology ◽

10.1093/annonc/mdy284.068 ◽

2018 ◽

Vol 29 ◽

pp. viii301

Author(s):

J.S. de Bono ◽

C. Higano ◽

F. Saad ◽

K. Miller ◽

M. Casey ◽

...

Keyword(s):

Prostate Cancer ◽

Dna Damage ◽

Phase Ii ◽

Hormonal Therapy ◽

Response Rate ◽

Phase Ii Study ◽

Open Label ◽

Castration Resistant ◽

Damage Repair

Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-1722 ◽

2009 ◽

Vol 15 (22) ◽

pp. 7099-7105 ◽

Cited By ~ 52

Author(s):

Mary-Ellen Taplin ◽

Meredith M. Regan ◽

Yoo-Joung Ko ◽

Glenn J. Bubley ◽

Stephen E. Duggan ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Synthesis Inhibition ◽

Androgen Synthesis ◽

Castration Resistant

900 OPEN-LABEL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF PERSONALIZED PEPTIDE VACCINATION (PPV) IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER(CRPC)

The Journal of Urology ◽

10.1016/j.juro.2011.02.2609 ◽

2011 ◽

Vol 185 (4S) ◽

Author(s):

Masanori Noguchi ◽

Fukuko Moriya ◽

Shigetaka Suekane ◽

Kei Matsuoka ◽

Gaku Arai ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Peptide Vaccination ◽

Open Label ◽

Castration Resistant ◽

Open Label Phase

Abstract A221: A phase II study of SB939 in patients with recurrent or metastatic castration resistant prostate cancer (CRPC).

10.1158/1535-7163.targ-11-a221 ◽

2011 ◽

Author(s):

Bernhard J. Eigl ◽

Scott North ◽

Nevin Murray ◽

Daniel YC Heng ◽

Eric Winquist ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant

Abstract CT161: A Phase II study of the polo-like kinase (PLK1) inhibitor onvansertib in combination with abiraterone (abi) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)

10.1158/1538-7445.am2019-ct161 ◽

2019 ◽

Cited By ~ 1

Author(s):

David J. Einstein ◽

Atish Choudhury ◽

Philip Saylor ◽

Lillian Werner ◽

Mark Erlander ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant